EXTON, PA — ProRx Pharma said it has significantly expanded its pharmaceutical manufacturing operations, adding new ISO-certified clean rooms, robotics, and automation as demand accelerates for compounded medications tied to preventative, functional, and longevity-focused care.
The privately held company said the investment is designed to raise standards for quality, safety, and scalability at a time when telehealth providers, concierge practices, and clinics are increasingly turning to compounded therapies to meet patient demand.
The expansion builds on a facility upgrade completed in February, when ProRx doubled the size of its existing pharmaceutical and manufacturing space. The latest phase includes a new hazardous drug ISO-8 processing room and a non-hazardous clean room dedicated to aseptic processing. Both spaces are equipped with automated systems intended to reduce technician handling, lower contamination risk, and increase production throughput.
ProRx said it is also constructing two additional aseptic processing clean rooms, one for hazardous drugs and one for nonhazardous drugs, to further increase capacity as order volumes rise.
All newly added spaces meet ISO-7 certification standards, with Primary Engineering Controls certified to ISO-5 for critical sterile operations. The company said those controls are revalidated every six months, a step aimed at maintaining strict sterility and regulatory compliance.
“Humans are the biggest source of contaminants in sterile drug processing,” said Kurt Lunkwitz, chief operating officer at ProRx. He said the introduction of automation and robotics reduces contamination risk while enabling electronic logging and quality controls aligned with regulatory best practices.
The upgrades are being driven by growing demand for compounded therapies such as Sermorelin, NAD+, Vitamin B12, MIC+B12 blends, Glutathione, and Testosterone. ProRx said combining advanced clean-room infrastructure with current good manufacturing practices allows it to support high-volume demand while still delivering patient-specific medications.
Company executives say the expanded facility positions ProRx to increase production capacity, improve operational efficiency, strengthen compliance controls, and support new service lines as preventative and longevity-focused medicine continues to grow.
“As this segment of care accelerates, providers need a 503B partner that can scale reliably,” Lunkwitz said. “These upgrades are meant to ensure consistency, safety, and regulatory confidence for healthcare partners nationwide.”
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.